No Data
Zhaoke Ophthalmology Shrinks Loss in 2024
ZHAOKE OPHTH-B (6622.HK): The pipeline has reached a critical point for realization, and it is an undervalued Innovative Drugs.
The three major important indications - drugs for children's myopia, dry eye syndrome, and wet age-related macular degeneration have already been or will soon be in the application status for market launch, expected to be introduced to the market within the next 1-2 years.
Understand the full-year performance of ZHAOKE OPHTH-B (6622.HK) in one chart for 2024.
Recently, ZHAOKE OPHTH-B (6622.HK) announced its performance for the year ending December 31, 2024. Let's take a look at the highlights of the company's performance through a chart.
ZHAOKE OPHTH-B (06622.HK) announced its annual performance with significant revenue growth, actively exploring licensing and cooperation opportunities Overseas.
On March 24, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that for the fiscal year ending December 31, 2024, the group recorded revenue of RMB 69.3 million, compared to RMB 18.8 million for the year ending December 31, 2023. The growth primarily stems from the company receiving milestone payments of RMB 33.5 million related to the product license agreement dated October 2, 2020, for Adapalene / Clindamycin hydrochloride compound gel, which increased licensing income. Additionally, the company is pleased to see breakthroughs in hospital coverage during the year, along with the successful implementation of innovative all-channel strategies.
ZHAOKE OPHTH-B (06622) announced its 2024 performance with a net loss of approximately 0.237 billion yuan, a year-on-year narrowing of 38.32%.
ZHAOKE OPHTH-B (06622) announced its 2024 performance, with a revenue of 69.324 million yuan, an increase of approximately 2% year-on-year...
Express News | Zhaoke Ophthalmology FY Revenue RMB 69.3 Million
